Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Description:** 2-(Oxalyl-amino)-benzoic acid is a small molecule compound belonging to the class of acylaminobenzoic acids. It is functionally related to anthranilic acid and has been primarily studied as a general, reversible, competitive inhibitor of protein tyrosine phosphatases (PTPs). The compound binds to the active site of PTPs, mimicking the natural substrate and forming hydrogen bonds with key residues in the enzyme's signature motif. This mechanism makes it an important scaffold for developing selective PTP inhibitors, which are considered potential therapeutic agents for diseases such as diabetes, cancer, and inflammation. However, as of now it is classified as an experimental or discovery agent without approved clinical indications[1][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2-(oxalyl-amino)-benzoic acid.